Background: Cardiac troponin I (cTnI) correlates with severity of myocardial injury. Nonspecific inflammation in congestive heart failure (CHF) could be assessed by C-reactive protein (CRP), haptoglobin (Hp), and ceruloplasmin (Cp) measurements.
Objectives: The aim of the study was to determine whether serum cTnI, CRP, Hp, and Cp concentrations differ among various stages of mitral valve disease (MVD) in dogs.
Materials And Methods: Dogs with MVD were allocated to 3 groups (I - asymptomatic; II - mild to moderate CHF; III advanced CHF) according to the scheme of the International Small Animal Cardiac Healthy Council (ISACHC). Concentrations of cTnI, CRP, Cp, and Hp were measured in all dogs upon admission, and cTnI and CRP were measured bimonthly during a 4-month follow-up period.
Results: In total 46 dogs with MVD were enrolled for the cross-sectional part (21 Group I, 11 Group II, 14 Group III), and 35 dogs were included in the longitudinal study. Initial mean Cp concentrations were similar among all groups. There was a statistically significant difference in Hp and CRP concentrations between group I (n = 21, P = .019) and III (n = 14, P < .001). There was a statistically significant decrease in CRP (P = .033) and cTnI (P = .009) concentrations over the longitudinal study (all groups). CRP concentrations were significantly higher in group I than III (P = .004). During the 6-month monitoring period of 35 dogs, there was a statistically significant positive correlation between cTnI and CRP (P < .001).
Conclusion: Differences in CRP concentrations between clinical stages of MVD suggest a clinically and therapeutically relevant inflammatory component.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/vcp.12278 | DOI Listing |
Anatol J Cardiol
December 2024
Biochemistry Laboratory, LR12ES05 "Nutrition-Functional Foods, and Vascular Health", Faculty of Medicine, University of Monastir, Monastir, Tunisia.
Background: There is increasing evidence that thrombomodulin (THBD) polymorphisms, along with inflammatory markers [i.e., C-reactive protein (CRP), fibrinogen, albumin], may increase the risk of acute myocardial infarction (AMI).
View Article and Find Full Text PDFAm J Transl Res
October 2024
Department of Emergency, Anxi County Hospital Quanzhou 362400, Fujian, China.
J Cardiovasc Thorac Res
June 2024
Department of Clinical Pharmacy, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.
Introduction: Percutaneous Coronary Intervention (PCI) is a fundamental procedure for coronary artery disease management, yet the risk of adverse events such periprocedural myocardial injury (PMI) persists. This double-blind, randomized clinical trial aims to assess the efficacy of empagliflozin in preventing myocardial injury during PCI procedure.
Methods: A total of 90 patients were randomly assigned to two groups A and B; Group A as the intervention group received empagliflozin 25 mg 24 hours before and empagliflozin 10 mg 1-2 hours before coronary intervention and group Bas the control group received placebo at similar intervals.
J Cardiothorac Surg
September 2024
Department of Cardiology, DeltaHealth Hospital•Shanghai, No. 109, Xule Road, Xujing Town, Qingpu District, Shanghai, 201702, China.
Cardiol Res
August 2024
Department of Cardiovascular Medicine, Chaohu Hospital of Anhui Medical University, Chaohu, China.
Background: Non-ST-segment elevation myocardial infarction (NSTEMI) is a common form of coronary artery disease, and its prognosis is influenced by multiple factors. This study aimed to analyze the predictive role of the combined application of cardiac troponin and cardiac function indices in NSTEMI patients' prognosis.
Methods: NSTEMI patients were screened and included in the study.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!